Liminatus Pharma, Inc. Class A Common Stock
LIMNLiminatus Pharma, Inc. Class A (LIMN) is a pharmaceutical company focused on developing and commercializing innovative therapies. The company emphasizes advancing treatments through cutting-edge research and scientific discovery, aiming to address unmet medical needs across various therapeutic areas.
$0.74 +0.02 (3.37%)
Company News
Liminatus Pharma, Inc. Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
Liminatus Pharma, a clinical-stage immuno-oncology company, has entered a Memorandum of Understanding with Capital Trust Group for a $30 million equity investment to support its research and development of advanced immunotherapy assets.
